AstraZeneca's SERENA-4 trial misses main goal for Etcamah in first-line breast cancerSep 14Clinical readoutAstraZenecacamizestrant
FDA approves AstraZeneca's Etcamah for HR-positive breast cancerSep 8Regulatory decisionAstraZenecacamizestrant
Results posted for onapristone-anastrozole trial in refractory endometrial cancerJul 17Trial updateanastrozoleContext Therapeutics Inc.
Sign inSign in